Old drug, new hope for right heart failure?

NCT ID NCT03344159

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested the drug spironolactone in 15 adults with chronic right-sided heart failure. The goal was to see if it is safe and can improve heart function and reduce stress on the heart. Participants took either the drug or a placebo to compare effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arrhythmogenic right ventricular cardiomyopathy chronic pulmonary heart disease congenital generalized lipodystrophy type 3 congestive heart failure cor pulmonale pulmonary arterial hypertension pulmonary hypertension pulmonary hypertension, primary, 2 pulmonary hypertension, primary, 3 pulmonary hypertension, primary, 4

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y4W7, Canada